CalciMedica Announces Proposed Public Offering of Common Stock
CalciMedica (Nasdaq: CALC), a clinical-stage biopharmaceutical company developing CRAC channel inhibition therapies, has announced a proposed underwritten public offering of common stock. The company plans to grant underwriters a 30-day option to purchase up to an additional 15% of the offered shares. Jones will serve as the sole book-running manager. The offering is being made through a shelf registration statement on Form S-3 previously filed with the SEC. The completion, size, and terms of the offering are subject to market conditions.
CalciMedica (Nasdaq: CALC), un'azienda biopharmaceutica in fase clinica che sviluppa terapie di inibizione dei canali CRAC, ha annunciato un'offerta pubblica sottoscritta di azioni ordinarie. L'azienda prevede di concedere agli underwriter un'opzione di 30 giorni per acquistare fino al 15% aggiuntivo delle azioni offerte. Jones agirà come unico gestore book-running. L'offerta è realizzata tramite una dichiarazione di registrazione a scaffale sul modulo S-3 precedentemente depositato presso la SEC. Il completamento, la dimensione e le condizioni dell'offerta sono soggetti alle condizioni di mercato.
CalciMedica (Nasdaq: CALC), una empresa biofarmacéutica en etapa clínica que desarrolla terapias de inhibición de canales CRAC, ha anunciado una propuesta de oferta pública garantizada de acciones ordinarias. La empresa planea otorgar a los suscriptores una opción de 30 días para comprar hasta un 15% adicional de las acciones ofrecidas. Jones actuará como único gerente de libro. La oferta se está realizando a través de una declaración de registro en estante en el formulario S-3 anteriormente presentada a la SEC. La finalización, el tamaño y los términos de la oferta están sujetos a las condiciones del mercado.
CalciMedica (Nasdaq: CALC)는 CRAC 채널 억제 요법을 개발하는 임상 단계의 생물 의약품 회사로, 보통주 공모 청약을 제안했다고 발표했습니다. 회사는 인수자에게 제공된 주식의 최대 15%를 구매할 수 있는 30일 옵션을 부여할 계획입니다. Jones는 단독 주관사가 될 것입니다. 이 제안은 SEC에 이전에 제출된 S-3 양식의 선반 등록 성명을 통해 이루어집니다. 제안의 완료, 규모 및 조건은 시장 상황에 따라 달라질 수 있습니다.
CalciMedica (Nasdaq: CALC), une entreprise bio-pharmaceutique en phase clinique développant des thérapies d'inhibition des canaux CRAC, a annoncé une offre publique souscrite d'actions ordinaires. L'entreprise prévoit d'accorder aux souscripteurs une option de 30 jours pour acheter jusqu'à 15% d'actions supplémentaires proposées. Jones servira en tant que gestionnaire principal. L'offre est réalisée par le biais d'une déclaration d'enregistrement sur étagère sur le formulaire S-3 précédemment déposé auprès de la SEC. La réalisation, la taille et les termes de l'offre sont soumis aux conditions du marché.
CalciMedica (Nasdaq: CALC), ein biopharmazeutisches Unternehmen in klinischer Phase, das Therapien zur Hemmung von CRAC-Kanälen entwickelt, hat ein vorgeschlagenes unterzeichnetes öffentliches Angebot von Stammaktien bekannt gegeben. Das Unternehmen plant, den Underwritern eine 30-tägige Option zu gewähren, um bis zu 15% zusätzlicher angebotener Aktien zu erwerben. Jones wird als alleiniger Buchführungsmanager fungieren. Das Angebot erfolgt über eine zuvor bei der SEC eingereichte Shelf-Registrierungsanmeldung auf Formular S-3. Der Abschluss, die Größe und die Bedingungen des Angebots unterliegen den Marktbedingungen.
- None.
- Potential shareholder dilution through new common stock issuance
- Uncertain completion of the offering due to market conditions
Insights
This public offering announcement signals potential dilution for existing shareholders of CalciMedica, a micro-cap biotech company. The lack of specified pricing and number of shares creates uncertainty around the scale of dilution. For a company with a market cap of just
The shelf registration (S-3) filed in August provides flexibility for raising capital, but timing suggests urgent cash needs. Biotech companies typically pursue public offerings when they need to fund clinical trials or operations. Without detailed terms, investors should monitor the preliminary prospectus supplement for pricing and volume to assess the dilutive impact.
All of the shares to be sold in the underwritten public offering are to be sold by the Company. In connection with the proposed offering, the Company expects to grant the underwriter a 30-day option to purchase up to an additional
Jones is acting as the sole book-running manager for the offering.
The underwritten public offering is being made pursuant to a shelf registration statement on Form S-3 (File No. 333-273949) (including a base prospectus) previously filed with the Securities and Exchange Commission (the "SEC") on August 11, 2023 and declared effective by the SEC on August 18, 2023. A preliminary prospectus supplement and the accompanying prospectus relating to and describing the terms of the underwritten public offering will be filed with the SEC and will be available on the SEC's website at www.sec.gov. When available, electronic copies of the preliminary prospectus supplement and the accompanying prospectus relating to the underwritten public offering may also be obtained by contacting: JonesTrading Institutional Services LLC, Attention: Equity Capital Markets, 325 Hudson Street, 6th Floor
This press release does not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or jurisdiction.
About CalciMedica
CalciMedica is a clinical-stage biopharmaceutical company focused on developing novel CRAC channel inhibition therapies for inflammatory and immunologic diseases. CalciMedica's proprietary technology targets the inhibition of CRAC channels to modulate the immune response and protect against tissue cell injury, with the potential to provide therapeutic benefits in life-threatening inflammatory and immunologic diseases for which there are currently no approved therapies. CalciMedica's lead product candidate Auxora™ has demonstrated positive and consistent clinical results in multiple completed efficacy clinical trials. CalciMedica has announced data for a Phase 2b trial (called CARPO – NCT04681066) in patients with AP with SIRS and completed a Phase 2 trial (called CARDEA – NCT04345614) in patients with COVID pneumonia. The Company is currently conducting a Phase 2 trial (called KOURAGE – NCT06374797) in patients with AKI with associated AHRF with data expected in 2025 and continuing to support the ongoing Phase 1/2 trial (called CRSPA – NCT04195347) in patients with AIPT with data expected in 2025. CalciMedica was founded by scientists from Torrey Pines Therapeutics and the Harvard CBR Institute for Biomedical Research, and is headquartered in La Jolla, CA.
Forward-Looking Statements
Any statements in this press release about future expectations, plans and prospects for CalciMedica, including statements about the timing, terms and completion of the underwritten public offering, and other statements containing the words "anticipate," "believe," "estimate," "expect," "intend," "may," "plan," "predict," "project," "target," "potential," "will," "would," "could," "should," "continue," and similar expressions, constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including: CalciMedica's inability, or the inability of the underwriter, to satisfy the conditions to closing for the proposed underwritten public offering; and economic, business, competitive, and/or regulatory factors affecting the business of CalciMedica generally. Additional risks and uncertainties that could cause actual outcomes and results to differ materially from those contemplated by the forward-looking statements are included under the caption "Risk Factors" in CalciMedica's Quarterly Report on Form 10-Q for the quarter ended June 30, 2024 filed with the SEC on August 12, 2024, and other filings CalciMedica makes with the SEC from time to time and available at www.sec.gov. All forward-looking statements contained in this press release speak only as of the date on which they were made. CalciMedica undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made, except as required by law.
CalciMedica Contact:
Investors and Media
Argot Partners
Sarah Sutton/Kevin Murphy
calcimedica@argotpartners.com
(212) 600-1902
View original content to download multimedia:https://www.prnewswire.com/news-releases/calcimedica-announces-proposed-public-offering-of-common-stock-302292103.html
SOURCE CalciMedica, Inc.
FAQ
What type of offering did CalciMedica (CALC) announce on October 30, 2024?
Who is the book-running manager for CalciMedica's (CALC) 2024 public offering?
What is the registration statement number for CalciMedica's (CALC) 2024 offering?
What is the primary business focus of CalciMedica (CALC)?
